Look out for XF-73 Destiny

Destiny Pharma (LON: DEST) expects to report on the study results of the phase 2b clinical study on the use of XF-73 nasal gel for the prevention of post-surgical infections by the end of March. finnCap believes that positive news would increase the broker’s valuation of Destiny by 80p a share.

Destiny is a developer of antimicrobial drugs. The main focus has been on XF-73, which is used to treat post-surgical infections, such as MRSA. There are also other potential uses of the XF platform, ...

You are unauthorized to view this page.

Previous articleNew Aquis admission: Samarkand
Next articleEntain records profit as online gaming jumps during pandemic
Avatar photo
Andrew Hore is the publisher of AIM Journal, which is an online monthly publication covering the Alternative Investment Market.